- Home
- SPKL vs PLX Comparison
SPKL vs PLX Comparison
Compare SPKL & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- PLX
- Stock Information
- Founded
- SPKL 2021
- PLX 1993
- Country
- SPKL United States
- PLX Israel
- Employees
- SPKL N/A
- PLX N/A
- Industry
- SPKL
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPKL
- PLX Health Care
- Exchange
- SPKL Nasdaq
- PLX Nasdaq
- Market Cap
- SPKL 174.6M
- PLX 160.2M
- IPO Year
- SPKL 2023
- PLX 1998
- Fundamental
- Price
- SPKL $10.67
- PLX $2.33
- Analyst Decision
- SPKL
- PLX
- Analyst Count
- SPKL 0
- PLX 0
- Target Price
- SPKL N/A
- PLX N/A
- AVG Volume (30 Days)
- SPKL 31.3K
- PLX 553.9K
- Earning Date
- SPKL 01-01-0001
- PLX 03-13-2025
- Dividend Yield
- SPKL N/A
- PLX N/A
- EPS Growth
- SPKL N/A
- PLX N/A
- EPS
- SPKL 0.19
- PLX N/A
- Revenue
- SPKL N/A
- PLX $45,667,000.00
- Revenue This Year
- SPKL N/A
- PLX N/A
- Revenue Next Year
- SPKL N/A
- PLX $90.00
- P/E Ratio
- SPKL $57.56
- PLX N/A
- Revenue Growth
- SPKL N/A
- PLX N/A
- 52 Week Low
- SPKL $10.18
- PLX $0.82
- 52 Week High
- SPKL $11.95
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- SPKL 61.48
- PLX 78.72
- Support Level
- SPKL $10.63
- PLX $2.11
- Resistance Level
- SPKL $10.68
- PLX $2.36
- Average True Range (ATR)
- SPKL 0.02
- PLX 0.12
- MACD
- SPKL 0.00
- PLX 0.00
- Stochastic Oscillator
- SPKL 85.71
- PLX 94.23
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.